NCI director Norman Sharpless to present annual Hardesty Lecture - Oct. 18

NCI director Norman Sharpless to present annual Hardesty Lecture - Oct. 18

The Power of Research, The Promise of Hope

The Annual Hardesty Lecture featuring NCI Director Dr. Norman “Ned” Sharpless will be held on Thursday, October 18, at 4:00 p.m. in the Okey Patteson Auditorium. (This lecture will be webcast for those who can not attend in person.)

Norman E. “Ned” Sharpless, M.D., was officially sworn in as the 15th director of the National Cancer Institute (NCI) on October 17, 2017. Prior to his appointment, Dr. Sharpless served as the director of the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, a position he held since January 2014.

Dr. Sharpless was a Morehead Scholar at UNC-Chapel Hill and received his undergraduate degree in mathematics. He went on to pursue his medical degree from the UNC School of Medicine, graduating with honors and distinction in 1993. He then completed his internal medicine residency at the Massachusetts General Hospital and a hematology/oncology fellowship at Dana-Farber/Partners Cancer Care, both of Harvard Medical School in Boston. 

After 2 years on the faculty at Harvard Medical School, he joined the faculty of the UNC School of Medicine in the Departments of Medicine and Genetics in 2002. He became the Wellcome Professor of Cancer Research at UNC in 2012. 

Dr. Sharpless is a member of the Association of American Physicians as well as the American Society for Clinical Investigation (ASCI), the nation’s oldest honor society for physician-scientists, and served on the ASCI council from 2011 to 2014. Dr. Sharpless was an associate editor of Aging Cell and deputy editor of the Journal of Clinical Investigation. He has authored more than 150 original scientific papers, reviews, and book chapters, and is an inventor on 10 patents. He co-founded two clinical-stage biotechnology companies: G1 Therapeutics and HealthSpan Diagnostics. 

In addition to serving as Director of NCI, Dr. Sharpless continues his research in understanding the biology of the aging process that promotes the conversion of normal self-renewing cells into dysfunctional cancer cells. Dr. Sharpless has made seminal contributions to the understanding of the relationship between aging and cancer, and in the preclinical development of novel therapeutics for melanoma, lung cancer, and breast cancer.

Hardesty Lecture Series The WVU Cancer Institute proudly presents the annual Hardesty Lecture, established by David and Susan Hardesty. This special lecture series brings renowned cancer scientists and physicians to the WVU campus for the benefit of the University and the Morgantown community. The series is an opportunity to bring experts to campus and provide extensive interactions with graduate students, medical practitioners for workshops and informal engagements that foster growth and encourage curiosity. It was created as a tribute to this couple’s loyal devotion and outstanding service to their alma mater and their tremendous impact on the University’s growth and development.

  • 2018 Cancer Burden Report Released

    WVU Cancer Institute's Cancer Prevention and Control, in collaboration with the West Virginia Cancer Registry, has released the 2018 Cancer Burden Report. The report provides updated statewide, age-adjusted incidence rates and counts for cancer diagnosed among West Virginia residents from 2011 to 2015.

    Read More

  • In the News: Richard Goldberg: A transformative leader in cancer research

    In the News: Richard Goldberg: A transformative leader in cancer research

    West Virginia University's Cancer Institute is well-known for its treatment and innovation. Leading the institute is Dr. Richard Goldberg, who has not only established himself as a transformative leader but also a potent researcher and educator.

    Read More

  • WVU Cancer Institute surgical oncologists perform new treatment for abdominal cancer

    WVU Cancer Institute surgical oncologists perform new treatment for abdominal cancer

    Brian Boone, M.D., surgical oncologist in the WVU Medicine Department of Surgery and WVU Cancer Institute, performed the state’s first hyperthermic intraperitoneal chemotherapy (HIPEC) infusion. This treatment delivers heated, sterilized chemotherapy to the abdomen as a treatment for cancer that has spread to the lining of the abdominal cavity, or peritoneum.

    Read More